Stockscreener 앱 받기
1.03
0.98%
0.01
시간 외 거래:
.98
-0.05
-4.85%
전일 마감가:
$1.02
열려 있는:
$1.04
하루 거래량:
99,409
Relative Volume:
0.56
시가총액:
$25.63M
수익:
$368.00K
순이익/손실:
$-9.54M
주가수익비율:
-2.1512
EPS:
-0.4788
순현금흐름:
$-9.47M
1주 성능:
+7.83%
1개월 성능:
+47.14%
6개월 성능:
+21.45%
1년 성능:
-27.97%
1일 변동 폭
$0.9711
$1.04
1주일 범위
$0.8713
$1.06
52주 변동 폭
$0.46
$1.69
Lexaria Bioscience Corp Stock (LEXX) Company Profile
명칭
Lexaria Bioscience Corp
전화
250-765-6424
주소
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.03 | 25.39M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Lexaria Bioscience (LEXX) Initiates 2026 Animal Study for Enhanced Formulations - GuruFocus
Lexaria Launches New GLP-1 Study to Expand Drug Delivery IP - TipRanks
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - Corsicana Daily Sun
Lexaria lines up rat study to test drug formulas for new patents - Stock Titan
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2026 - marketscreener.com
Lexaria Bioscience Corp reports results for the quarter ended February 28Earnings Summary - TradingView — Track All Markets
LEXARIA BIOSCIENCE ($LEXX) Releases Q2 2026 Earnings - Quiver Quantitative
Lexaria 10-Q: Revenue $0.02M, EPS $(0.13) for Six Months Ended Feb 28, 2026 - TradingView — Track All Markets
Lexaria Bioscience (NASDAQ: LEXX) revenue plunges as going concern risk emerges - Stock Titan
Lexaria Bioscience Corp.Warrant (NQ: LEXXW - FinancialContent
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Bioscience Corp expected to post a loss of 9 cents a shareEarnings Preview - TradingView — Track All Markets
Published on: 2026-04-09 10:10:06 - baoquankhu1.vn
Short Covering: Can Lexaria Bioscience Corp sustain its profitabilityRisk Management & Long Hold Capital Preservation Plans - baoquankhu1.vn
Quarterly Risk: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growthGap Up & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
LEXX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lexaria Bioscience Corp. (LEXX) Stock: Oral Obesity Drug Momentum Fuels Innovation Outlook - parameter.io
Lexaria Eyes Growing Oral GLP-1 Market After Eli Lilly’s Foundayo Approval - TipRanks
Lexaria Applauds Eli Lilly's Foundayo Drug Approval - Investing News Network
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - The Joplin Globe
A third oral GLP-1 wins FDA approval, and Lexaria sees an opening - Stock Titan
Portfolio Shifts: What hedge funds are buying CSBRBuy Signal & Reliable Breakout Forecasts - baoquankhu1.vn
Lexaria signs contract for semaglutide drug delivery study By Investing.com - Investing.com South Africa
LEXX Technical Analysis & Stock Price Forecast - Intellectia AI
Lexaria Bioscience Corp. (LEXX) Stock Price, News, Quote & History - ca.finance.yahoo.com
Lexaria Launches New Human Trial to Advance Oral GLP-1 Drug Delivery Platform - TipRanks
Aug Retail: Will Lexaria Bioscience Corp Equity Warrant outperform tech stocks2026 Major Catalysts & Smart Investment Allocation Tips - baoquankhu1.vn
Lexaria to Begin New Human Clinical Study in GLP-1 - Investing News Network
Lexaria signs contract for semaglutide drug delivery study - Investing.com
Lexaria Bioscience to Launch New Clinical Study Comparing Enhanced Oral GLP-1 Formulations to Market Leaders - citybuzz -
Lexaria Bioscience (LEXX) Launches Key Human Pilot Study - GuruFocus
A 5-week human trial will test Lexaria's oral GLP-1 against Wegovy - Stock Titan
Can Lexaria Bioscience Corp sustain its profitability2026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Lexaria Bioscience files to sell 2.76M shares of common stock for holders - MSN
Sentiment Review: What is Lexaria Bioscience Corp Equity Warrants revenue forecastDividend Hike & High Accuracy Trade Alerts - baoquankhu1.vn
Institution Moves: Can Lexaria Bioscience Corp lead its sector in growth - baoquankhu1.vn
History Review: What hedge funds are buying Lexaria Bioscience Corp2026 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Risk Analysis: Can Lexaria Bioscience Corp expand into new marketsEarnings Beat & High Conviction Trade Alerts - baoquankhu1.vn
Weekly Earnings: Can Lexaria Bioscience Corp sustain its profitability2026 Action & Verified Short-Term Plans - baoquankhu1.vn
Lexaria receives 5 patents including 2 for diabetes treatment By Investing.com - Investing.com Australia
Stock Recap: Will Lexaria Bioscience Corp Equity Warrant face regulatory challenges2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Lexaria Bolsters Global Patent Portfolio With New GLP-1 and Cardiometabolic IP - TipRanks
Lexaria's Robust Patent Portfolio Continues to Grow - Investing News Network
LEXX Advances with New Patents for Hypertension, Epilepsy, and D - GuruFocus
Lexaria receives 5 patents including 2 for diabetes treatment - Investing.com
Five new patents extend Lexaria's diabetes and epilepsy claims into 2044 - Stock Titan
FOMO Trade: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
Aug Intraday: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Market Mood & Daily Entry Point Alerts - baoquankhu1.vn
Moving Averages: Will Lexaria Bioscience Corp Equity Warrant stock go up in YEARShare Buyback & Daily Entry Point Alerts - baoquankhu1.vn
Lexaria pursues oral GLP-1 drug delivery partnerships By Investing.com - Investing.com Australia
If You Invested $1,000 in Lexaria Bioscience Corp (LEXX) - Stock Titan
Lexaria Bioscience Corp (LEXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):